Posco Chemical successfully sells maiden ESG bond Bond sale attracts bids worth nearly 5.5 times of its offering
Translated by Kim So-in 공개 2022-04-08 08:06:09
이 기사는 2022년 04월 08일 08:03 thebell 에 표출된 기사입니다.
Posco Chemical has successfully sold its maiden ESG (environmental, social and governance) bond despite worries over interest rate hikes.Posco Chemical attracted bids of 800 billion won ($656 million) in its bookbuilding session on Wednesday, which is nearly 5.5 times of its issuance of 150 billion won, according to industry sources. It attracted bids worth 640 billion won for a 100 billion won 3-year bond issue and 160 billion won for a 50 billion won 5–year bond issue.
The 3-year bond was priced at 10 basis points (bps) lower than its average yield and the 5-year bond at 3 bps lower than its average yield. Posco Chemical proposed yields ranging from minus 30 to plus 30 bps of the average yield for its bonds.
Posco Chemical planned to increase the offering to up to 300 billion and is expected to discuss details to proceed with the plan. The bonds will likely be issued at yields lower than the average yield even if it increases the offering.
The latest issuance has proved positive investor sentiment on “good” deals despite depressed corporate bond market, market watchers said. South Korea’s major institutional investors and some foreign banks reportedly participated in the bookbuilding process.
Investors are attracted to high growth potential of secondary battery materials. Posco Chemical’s energy materials division propelled the record performance, with the division’s revenue spiking about 60% in 2021 compared to the previous year.
The latest deal marks the company’s first ESG bond sale, which will entirely be issued in green bonds. (Reporting by Yoon-shin Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '탈모사업 선전' 메타랩스, 1분기 매출 115%↑
- [HLB '리보세라닙' 미국 진출기]불발된 국산 항암제 첫 미국 진출, FDA 사실상 '승인 거절'
- 한화생명, 제도 강화에 킥스비율 하락…연 목표 하향
- [CJ온스타일 vs GS홈쇼핑]리더십의 변화, 홈쇼핑 체질 개선 '속도전'
- [HLB '리보세라닙' 미국 진출기]허가 불발, CRL 수령…진양곤 회장 "리보세라닙 문제 아냐"
- BNK캐피탈, 라오스 MFI법인 운영자금 수혈 나서
- [보험사 해외사업 점검]현대해상, 베트남 법인 가파른 성장에 지분 확대 '시동'
- [금융지주 CEO 책임경영 진단]진옥동 회장의 '자사주 사랑'…평가액 '9억' 4대 금융 최대
- 대구은행, 제7 시중은행으로…내부통제 개선 노력 인정
- [Company Watch]엔켐, 주가 고공행진에 첫 '전환청구'